The layered zirconium glycine-N,N-dimethylphosphonate (ZGDMP) was prepared and the intercalation behavior of n-alkylmonoamines was investigated. The X-ray diffraction powder patterns demonstrated that the n-alkylmonoa...The layered zirconium glycine-N,N-dimethylphosphonate (ZGDMP) was prepared and the intercalation behavior of n-alkylmonoamines was investigated. The X-ray diffraction powder patterns demonstrated that the n-alkylmonoamines were taken up in one step and there were no other intermediate phases. The interlayer distance correlated with the number of carbon atoms of the n-alkylmonoamine chains. The n-alkylmonoamines were intercalated into ZGDMP in such a way that the protons of the interlayer -CO2H groups were replaced by the terminal -NH3+ of the protonated n-alkylmonoamines. The intercalated n-alkylmonoamines were released from the lamellar ZGDMP at temperature of 150 to 250 ℃.展开更多
阿尔茨海默病(Alzheimer’s Disease, AD)是最常见的与年龄相关的不可逆和进行性神经退行性疾病之一,其特征是失智、记忆力减退、语言技能下降以及随着年龄的增长而出现认知障碍。目前的治疗药物主要以改善临床症状为主,本文通过查阅相...阿尔茨海默病(Alzheimer’s Disease, AD)是最常见的与年龄相关的不可逆和进行性神经退行性疾病之一,其特征是失智、记忆力减退、语言技能下降以及随着年龄的增长而出现认知障碍。目前的治疗药物主要以改善临床症状为主,本文通过查阅相关文献,将主要与AD相关且受美国食品药物管理局(Food and Drug Administration, FDA)所批准的治疗药物做一综述,本文系统地总结和分析当前治疗药物在AD治疗中的作用以及研究进展,以此为AD的治疗和研究提供参考和借鉴。展开更多
文摘The layered zirconium glycine-N,N-dimethylphosphonate (ZGDMP) was prepared and the intercalation behavior of n-alkylmonoamines was investigated. The X-ray diffraction powder patterns demonstrated that the n-alkylmonoamines were taken up in one step and there were no other intermediate phases. The interlayer distance correlated with the number of carbon atoms of the n-alkylmonoamine chains. The n-alkylmonoamines were intercalated into ZGDMP in such a way that the protons of the interlayer -CO2H groups were replaced by the terminal -NH3+ of the protonated n-alkylmonoamines. The intercalated n-alkylmonoamines were released from the lamellar ZGDMP at temperature of 150 to 250 ℃.
文摘阿尔茨海默病(Alzheimer’s Disease, AD)是最常见的与年龄相关的不可逆和进行性神经退行性疾病之一,其特征是失智、记忆力减退、语言技能下降以及随着年龄的增长而出现认知障碍。目前的治疗药物主要以改善临床症状为主,本文通过查阅相关文献,将主要与AD相关且受美国食品药物管理局(Food and Drug Administration, FDA)所批准的治疗药物做一综述,本文系统地总结和分析当前治疗药物在AD治疗中的作用以及研究进展,以此为AD的治疗和研究提供参考和借鉴。
